ROYALTY PHARMA PLC- CL A (RPRX) Stock Fundamental Analysis

NASDAQ:RPRX • GB00BMVP7Y09

45.36 USD
+0.21 (+0.47%)
At close: Feb 26, 2026
45.36 USD
0 (0%)
After Hours: 2/26/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

RPRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. RPRX has an excellent profitability rating, but there are some minor concerns on its financial health. RPRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • RPRX had positive earnings in the past year.
  • In the past year RPRX had a positive cash flow from operations.
  • In the past 5 years RPRX has always been profitable.
  • In the past 5 years RPRX always reported a positive cash flow from operatings.
RPRX Yearly Net Income VS EBIT VS OCF VS FCFRPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

1.2 Ratios

  • The Return On Assets of RPRX (3.93%) is better than 85.42% of its industry peers.
  • Looking at the Return On Equity, with a value of 11.90%, RPRX belongs to the top of the industry, outperforming 86.46% of the companies in the same industry.
  • The Return On Invested Capital of RPRX (6.49%) is better than 84.90% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for RPRX is significantly below the industry average of 12.96%.
Industry RankSector Rank
ROA 3.93%
ROE 11.9%
ROIC 6.49%
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
RPRX Yearly ROA, ROE, ROICRPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • The Profit Margin of RPRX (32.42%) is better than 95.31% of its industry peers.
  • RPRX's Profit Margin has improved in the last couple of years.
  • RPRX has a better Operating Margin (65.58%) than 100.00% of its industry peers.
  • RPRX's Operating Margin has declined in the last couple of years.
Industry RankSector Rank
OM 65.58%
PM (TTM) 32.42%
GM N/A
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
RPRX Yearly Profit, Operating, Gross MarginsRPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RPRX is destroying value.
  • RPRX has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RPRX has been increased compared to 5 years ago.
  • RPRX has a worse debt/assets ratio than last year.
RPRX Yearly Shares OutstandingRPRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
RPRX Yearly Total Debt VS Total AssetsRPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • Based on the Altman-Z score of 1.80, we must say that RPRX is in the distress zone and has some risk of bankruptcy.
  • RPRX has a better Altman-Z score (1.80) than 61.98% of its industry peers.
  • RPRX has a debt to FCF ratio of 11.30. This is a negative value and a sign of low solvency as RPRX would need 11.30 years to pay back of all of its debts.
  • The Debt to FCF ratio of RPRX (11.30) is better than 79.69% of its industry peers.
  • A Debt/Equity ratio of 1.32 is on the high side and indicates that RPRX has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.32, RPRX is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 11.3
Altman-Z 1.8
ROIC/WACC0.75
WACC8.65%
RPRX Yearly LT Debt VS Equity VS FCFRPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B

2.3 Liquidity

  • RPRX has a Current Ratio of 2.40. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of RPRX (2.40) is comparable to the rest of the industry.
  • RPRX has a Quick Ratio of 2.40. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.40, RPRX perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.4
RPRX Yearly Current Assets VS Current LiabilitesRPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 8.05% over the past year.
  • Measured over the past 5 years, RPRX shows a small growth in Earnings Per Share. The EPS has been growing by 0.60% on average per year.
  • RPRX shows a small growth in Revenue. In the last year, the Revenue has grown by 5.06%.
  • RPRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.30% yearly.
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.82% on average over the next years. This is quite good.
  • Based on estimates for the next years, RPRX will show a quite strong growth in Revenue. The Revenue will grow by 8.88% on average per year.
EPS Next Y17.09%
EPS Next 2Y15.54%
EPS Next 3Y16.12%
EPS Next 5Y10.82%
Revenue Next Year4.65%
Revenue Next 2Y4.83%
Revenue Next 3Y5.2%
Revenue Next 5Y8.88%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 10.24 indicates a reasonable valuation of RPRX.
  • RPRX's Price/Earnings ratio is rather cheap when compared to the industry. RPRX is cheaper than 92.19% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of RPRX to the average of the S&P500 Index (27.11), we can say RPRX is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 8.75, the valuation of RPRX can be described as very reasonable.
  • RPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. RPRX is cheaper than 91.15% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.13, RPRX is valued rather cheaply.
Industry RankSector Rank
PE 10.24
Fwd PE 8.75
RPRX Price Earnings VS Forward Price EarningsRPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 82.29% of the companies in the same industry are more expensive than RPRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 33.06
EV/EBITDA N/A
RPRX Per share dataRPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • RPRX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as RPRX's earnings are expected to grow with 16.12% in the coming years.
PEG (NY)0.6
PEG (5Y)17.1
EPS Next 2Y15.54%
EPS Next 3Y16.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 2.08%, RPRX has a reasonable but not impressive dividend return.
  • RPRX's Dividend Yield is rather good when compared to the industry average which is at 1.07. RPRX pays more dividend than 92.71% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.80, RPRX has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.08%

5.2 History

  • RPRX has been paying a dividend for over 5 years, so it has already some track record.
  • RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
RPRX Yearly Dividends per shareRPRX Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • RPRX pays out 49.06% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.06%
EPS Next 2Y15.54%
EPS Next 3Y16.12%
RPRX Yearly Income VS Free CF VS DividendRPRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B
RPRX Dividend Payout.RPRX Dividend Payout, showing the Payout Ratio.RPRX Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (2/26/2026, 8:00:02 PM)

After market: 45.36 0 (0%)

45.36

+0.21 (+0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)05-06
Inst Owners81.5%
Inst Owner Change7.14%
Ins Owners1.56%
Ins Owner Change8.14%
Market Cap26.18B
Revenue(TTM)2.38B
Net Income(TTM)770.95M
Analysts85.71
Price Target48.57 (7.08%)
Short Float %6.82%
Short Ratio6.48
Dividend
Industry RankSector Rank
Dividend Yield 2.08%
Yearly Dividend0.65
Dividend Growth(5Y)N/A
DP49.06%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.34%
Min EPS beat(2)8.69%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-9.55%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.66%
EPS beat(12)9
Avg EPS beat(12)0.82%
EPS beat(16)10
Avg EPS beat(16)-0.51%
Revenue beat(2)1
Avg Revenue beat(2)-7.72%
Min Revenue beat(2)-23.38%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)-0.41%
Min Revenue beat(4)-23.38%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-7.18%
Revenue beat(12)3
Avg Revenue beat(12)-9.25%
Revenue beat(16)3
Avg Revenue beat(16)-10.51%
PT rev (1m)4.81%
PT rev (3m)5.59%
EPS NQ rev (1m)4.64%
EPS NQ rev (3m)3.74%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.4%
Revenue NQ rev (1m)94.83%
Revenue NQ rev (3m)92.45%
Revenue NY rev (1m)2.96%
Revenue NY rev (3m)5.18%
Valuation
Industry RankSector Rank
PE 10.24
Fwd PE 8.75
P/S 11.01
P/FCF 33.06
P/OCF 10.52
P/B 4.04
P/tB 4.72
EV/EBITDA N/A
EPS(TTM)4.43
EY9.77%
EPS(NY)5.19
Fwd EY11.43%
FCF(TTM)1.37
FCFY3.03%
OCF(TTM)4.31
OCFY9.51%
SpS4.12
BVpS11.22
TBVpS9.62
PEG (NY)0.6
PEG (5Y)17.1
Graham Number33.44
Profitability
Industry RankSector Rank
ROA 3.93%
ROE 11.9%
ROCE 8.21%
ROIC 6.49%
ROICexc 7.04%
ROICexgc 7.44%
OM 65.58%
PM (TTM) 32.42%
GM N/A
FCFM 33.31%
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
ROICexc(3y)7.21%
ROICexc(5y)6.98%
ROICexgc(3y)7.34%
ROICexgc(5y)7.06%
ROCE(3y)8.34%
ROCE(5y)7.84%
ROICexgc growth 3Y10.47%
ROICexgc growth 5Y-5.87%
ROICexc growth 3Y8.49%
ROICexc growth 5Y-6.85%
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 11.3
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 71.39%
Interest Coverage -5.64
Cash Conversion N/A
Profit Quality 102.74%
Current Ratio 2.4
Quick Ratio 2.4
Altman-Z 1.8
F-Score5
WACC8.65%
ROIC/WACC0.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)90.64%
Cap/Sales(5y)89.1%
Profit Quality(3y)70.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
EPS Next Y17.09%
EPS Next 2Y15.54%
EPS Next 3Y16.12%
EPS Next 5Y10.82%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%
Revenue Next Year4.65%
Revenue Next 2Y4.83%
Revenue Next 3Y5.2%
Revenue Next 5Y8.88%
EBIT growth 1Y20.66%
EBIT growth 3Y19.11%
EBIT growth 5Y-1.25%
EBIT Next Year12.12%
EBIT Next 3Y11.79%
EBIT Next 5Y11.11%
FCF growth 1Y200.85%
FCF growth 3Y25.33%
FCF growth 5YN/A
OCF growth 1Y-10.08%
OCF growth 3Y5.11%
OCF growth 5Y4.12%

ROYALTY PHARMA PLC- CL A / RPRX FAQ

Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?

ChartMill assigns a fundamental rating of 6 / 10 to RPRX.


What is the valuation status for RPRX stock?

ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.


How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?

ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for RPRX stock?

The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.24 and the Price/Book (PB) ratio is 4.04.


Can you provide the dividend sustainability for RPRX stock?

The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.06%.